Cargando…

An observational study of alemtuzumab following fingolimod for multiple sclerosis

OBJECTIVE: To describe a series of patients with relapsing multiple sclerosis (MS) who experienced significant and unexpected disease activity within the first 12 months after switching from fingolimod to alemtuzumab. METHODS: Patients with relapsing MS treated sequentially with fingolimod then alem...

Descripción completa

Detalles Bibliográficos
Autores principales:	Willis, Mark, Pearson, Owen, Illes, Zsolt, Sejbaek, Tobias, Nielsen, Christian, Duddy, Martin, Petheram, Kate, van Munster, Caspar, Killestein, Joep, Malmeström, Clas, Tallantyre, Emma, Robertson, Neil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226279/ https://www.ncbi.nlm.nih.gov/pubmed/28101520 http://dx.doi.org/10.1212/NXI.0000000000000320

Ejemplares similares

Alemtuzumab for Multiple Sclerosis
por: Willis, Mark D., et al.
Publicado: (2016)

Alemtuzumab for the treatment of multiple sclerosis
por: Willis, Mark D, et al.
Publicado: (2015)

Emerging safety issues in alemtuzumab-treated MS patients
por: Killestein, Joep, et al.
Publicado: (2019)

A five-year observational prospective mono-center study of the efficacy of alemtuzumab in a real-world cohort of patients with multiple sclerosis
por: Sandgren, Sofia, et al.
Publicado: (2023)

The role of autoimmune antibodies to predict secondary autoimmunity in patients with relapsing-remitting multiple sclerosis treated with alemtuzumab: A nationwide prospective survey
por: Sandgren, Sofia, et al.
Publicado: (2023)

Patient Attitudes to Routine Cognitive Testing in Multiple Sclerosis
por: Mortensen, Gitte Lee, et al.
Publicado: (2020)

Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing–remitting multiple sclerosis: an observational study
por: Zhukovsky, Christina, et al.
Publicado: (2021)

Long-term structural retinal changes in patients with optic neuritis related to multiple sclerosis
por: Andersen, Maria Rene, et al.
Publicado: (2017)

Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond
por: Ruck, Tobias, et al.
Publicado: (2015)

Alemtuzumab in the treatment of multiple sclerosis
por: Fernandez, Óscar
Publicado: (2014)

Detecting and predicting neutralization of alemtuzumab responses in MS
por: Saxena, Gauri, et al.
Publicado: (2020)

Determination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod
por: David, Olivier J., et al.
Publicado: (2017)

Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients
por: Leurs, Cyra E, et al.
Publicado: (2017)

The Urine Proteome Profile Is Different in Neuromyelitis Optica Compared to Multiple Sclerosis: A Clinical Proteome Study
por: Nielsen, Helle H., et al.
Publicado: (2015)

Role of Monoclonal Antibody "Alemtuzumab" in the Treatment of Multiple Sclerosis
por: Nosher, Sadia, et al.
Publicado: (2021)

Alemtuzumab
por: Tridente, Giuseppe
Publicado: (2013)

Impact of FcγR variants on the response to alemtuzumab in multiple sclerosis
por: Keller, Christian W., et al.
Publicado: (2019)

MicroRNA regulate immune pathways in T-cells in multiple sclerosis (MS)
por: Jernås, Margareta, et al.
Publicado: (2013)

Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis
por: Gross, Catharina C., et al.
Publicado: (2016)

Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program
por: Havrdova, Eva, et al.
Publicado: (2017)

Multiple Sclerosis Relapses Following Cessation of Fingolimod
por: Malpas, Charles B., et al.
Publicado: (2022)

Alemtuzumab: evidence for its potential in relapsing—remitting multiple sclerosis
por: Brown, JWL, et al.
Publicado: (2013)

Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis
por: Babij, Rachel, et al.
Publicado: (2015)

Intractable and highly active relapsing multiple sclerosis – role of alemtuzumab
por: Dubey, Divyanshu, et al.
Publicado: (2015)

Alemtuzumab in the treatment of multiple sclerosis: patient selection and special considerations
por: Dörr, Jan, et al.
Publicado: (2016)

Autoimmune thyroid disease following treatment with alemtuzumab for multiple sclerosis
por: Alamo, Angela, et al.
Publicado: (2019)

The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis
por: Rolla, Simona, et al.
Publicado: (2020)

Thyroid Autoimmunity Following Alemtuzumab Treatment in Multiple Sclerosis Patients
por: Kazakou, Paraskevi, et al.
Publicado: (2021)

Continuous evolution of magnetic resonance imaging in multiple sclerosis
por: Tallantyre, E. C., et al.
Publicado: (2016)

Intrathecal kappa free light chain synthesis is associated with worse prognosis in relapsing–remitting multiple sclerosis
por: Rosenstein, Igal, et al.
Publicado: (2023)

Searching for neurodegeneration in multiple sclerosis at clinical onset: Diagnostic value of biomarkers
por: Novakova, Lenka, et al.
Publicado: (2018)

Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis
por: Li, Kai, et al.
Publicado: (2017)

Early MRI predictors of prognosis in multiple sclerosis
por: Davda, Nikunj, et al.
Publicado: (2019)

Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
por: Lorscheider, Johannes, et al.
Publicado: (2020)

Alemtuzumab in Multiple Sclerosis: Short- and Long-Term Effects of Immunodepletion on the Peripheral Treg Compartment
por: Haas, Jürgen, et al.
Publicado: (2019)

Comparison of neurofilament light chain results between two independent facilities
por: Sejbaek, Tobias, et al.
Publicado: (2020)

CSF orexin-A levels after rituximab treatment in recent onset narcolepsy type 1
por: Wasling, Pontus, et al.
Publicado: (2019)

Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry
por: Papp, Viktoria, et al.
Publicado: (2021)

Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis
por: Warnke, Clemens, et al.
Publicado: (2011)

Myeloid cells as target of fingolimod action in multiple sclerosis
por: Di Dario, Marco, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_vt64j48d38l4t1kesf4u8t55u5